TG Therapeutics Inc Asset Resilience Ratio
TG Therapeutics Inc asset resilience ratio. TG Therapeutics Inc (TGTX) has an Asset Resilience Ratio of 4.25% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TG Therapeutics Inc (TGTX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TG Therapeutics Inc (2003–2025)
Asset resilience ratio of TG Therapeutics Inc from 2003 to 2025. This chart shows how TG Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of TG Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TG Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TG Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $69.67 Million | 4.25% |
| Total Liquid Assets | $69.67 Million | 4.25% |
Asset Resilience Insights
- Limited Liquidity: TG Therapeutics Inc maintains only 4.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TG Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare TG Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
TG Therapeutics Inc Asset Resilience Ratio by Year (2003–2025)
TG Therapeutics Inc asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for TG Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.91% | $62.82 Million | $1.06 Billion | -16.79pp |
| 2024-12-31 | 22.69% | $131.11 Million | $577.69 Million | -15.10pp |
| 2023-12-31 | 37.80% | $124.58 Million | $329.59 Million | +7.12pp |
| 2022-12-31 | 30.67% | $59.37 Million | $193.57 Million | +26.49pp |
| 2021-12-31 | 4.18% | $15.88 Million | $379.63 Million | -4.13pp |
| 2020-12-31 | 8.31% | $51.99 Million | $625.64 Million | -8.74pp |
| 2019-12-31 | 17.05% | $27.80 Million | $163.01 Million | -15.06pp |
| 2018-12-31 | 32.11% | $26.85 Million | $83.62 Million | +3.36pp |
| 2017-12-31 | 28.75% | $28.00 Million | $97.38 Million | -7.49pp |
| 2016-12-31 | 36.24% | $19.85 Million | $54.78 Million | +16.71pp |
| 2015-12-31 | 19.53% | $22.17 Million | $113.47 Million | -7.05pp |
| 2014-12-31 | 26.59% | $23.06 Million | $86.75 Million | +16.31pp |
| 2013-12-31 | 10.28% | $4.95 Million | $48.11 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $22.07 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $15.91 Million | -- |
| 2008-12-31 | 58.45% | $730.00K | $1.25 Million | +49.46pp |
| 2005-12-31 | 8.99% | $1.01 Million | $11.21 Million | -70.91pp |
| 2004-12-31 | 79.90% | $4.51 Million | $5.65 Million | +75.39pp |
| 2003-12-31 | 4.52% | $352.15K | $7.80 Million | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more